Charles E. Aldinger

High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1

John McNeish, Robert J. Aiello, Deborah J. Guyot et al. · Proceedings of the National Academy of Sciences · 2000 · 539 citations · Full text

Genetics, Tangier Disease, Foam Cell Accumulation +21

Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners

Banavara L. Mylari, Eric R. Larson, Thomas A. Beyer et al. · Journal of Medicinal Chemistry · 1991 · 244 citations · Full text

CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats

M.J. Peterson, Reinhard Sarges, Charles E. Aldinger et al. · Metabolism · 1979 · 137 citations

Metabolic Syndrome, Aldo-keto Reductase, Biochemistry +9

Red Blood Cell Sorbitol as an Indicator of Polyol Pathway Activity: Inhibition by Sorbinil in Insulin-dependent Diabetic Subjects

John I. Malone, Hanzel Leavengood, Michael J. Peterson et al. · Diabetes · 1984 · 91 citations

Polysaccharide, Insulin Signaling, Metabolic Syndrome +16

Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors

Christopher A. Lipinski, Charles E. Aldinger, Thomas A. Beyer et al. · Journal of Medicinal Chemistry · 1992 · 40 citations · Full text